Clearside Biomedical (CLSD) IPO Opens Up 14%

Today's IPO for Clearside Biomedical, Inc. (Nasdaq: CLSD) opened for trading at $8 after pricing 7,200,000 shares of its common stock at a public offering price of $7.00 per share.

Cowen and Company and Stifel are serving as joint book-running managers for the offering. Needham & Company and Wedbush PacGrow are serving as co-managers.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space (SCS™) microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye.

You May Also Be Interested In

• ITG launches IPO roadshow, seeks Nasdaq listing at up to $22 per share
• Kalshi in early talks for IPO - The Information
• Lime seeks up to $1.66 billion valuation in US IPO